Intellia Therapeutics (NTLA) VP sells shares to cover RSU tax
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Intellia Therapeutics, Inc. executive Michael P. Dube, VP and Chief Accounting Officer, reported a sale of 2,641 shares of common stock on July 1, 2026 at a weighted average price of $16.78 per share.
According to the disclosure, this was a mandatory “sell-to-cover” transaction to satisfy tax withholding obligations triggered by the vesting of restricted stock units (RSUs) on the same date, and is explicitly described as not a voluntary trade. After this tax-related sale, Dube held 66,886 shares of Intellia common stock directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 2,641 shares ($44,316)
Net Sell
1 txn
Insider
Dube Michael P
Role
VP, Chief Accounting Officer
Sold
2,641 shs ($44K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 2,641 | $16.78 | $44K |
Holdings After Transaction:
Common Stock — 66,886 shares (Direct)
Footnotes (1)
- Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on July 1, 2026, and does not represent a volitional trade by the Reporting Person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.78 to $17.12, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 1, 2026 at each separate price.
Key Figures
Shares sold: 2,641 shares
Weighted average sale price: $16.78 per share
Shares held after transaction: 66,886 shares
+1 more
4 metrics
Shares sold
2,641 shares
Mandatory sell-to-cover on July 1, 2026
Weighted average sale price
$16.78 per share
Open-market sale with prices from $16.78 to $17.12
Shares held after transaction
66,886 shares
Direct ownership following July 1, 2026 sale
RSU vesting date
July 1, 2026
Triggered tax withholding and sell-to-cover transaction
Key Terms
sell-to-cover, RSUs, weighted average price, open-market sale
4 terms
sell-to-cover financial
"Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation"
Sell-to-cover is when part of newly issued or exercised company stock is immediately sold to pay required taxes and fees, so the recipient keeps the remaining shares. For investors this matters because it reduces the number of shares insiders or employees actually hold after a grant, can create small, routine share sales that aren’t signal of cashing out, and slightly increases share supply on the market—like selling a portion of a paycheck to cover the tax bill.
RSUs financial
"tax withholding obligation upon the vesting of RSUs on July 1, 2026"
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
FAQ
What insider transaction did Intellia Therapeutics (NTLA) report for Michael P. Dube?
Intellia Therapeutics reported that VP and Chief Accounting Officer Michael P. Dube sold 2,641 shares of common stock. The sale occurred on July 1, 2026 and was tied to RSU vesting and related tax withholding obligations, rather than a discretionary open-market trade.
What role does Michael P. Dube hold at Intellia Therapeutics (NTLA)?
Michael P. Dube is identified as an officer of Intellia Therapeutics, serving as Vice President and Chief Accounting Officer. His position is disclosed in the Form 4, which reports his equity transaction and confirms he is not listed as a director or a 10% beneficial owner.